205 related articles for article (PubMed ID: 35303241)
1. Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal growth factor receptor.
Knoche SM; Larson AC; Brumfield GL; Cate S; Hildebrand WH; Solheim JC
Immunol Res; 2022 Jun; 70(3):371-391. PubMed ID: 35303241
[TBL] [Abstract][Full Text] [Related]
2. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
[TBL] [Abstract][Full Text] [Related]
3. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
Quinn LL; Williams LR; White C; Forrest C; Zuo J; Rowe M
J Virol; 2016 Jan; 90(1):356-67. PubMed ID: 26468525
[TBL] [Abstract][Full Text] [Related]
4. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
[TBL] [Abstract][Full Text] [Related]
5. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy.
Ali S; El-Rayes BF; Sarkar FH; Philip PA
Mol Cancer Ther; 2005 Dec; 4(12):1943-51. PubMed ID: 16373709
[TBL] [Abstract][Full Text] [Related]
7. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
8. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
9. Correlation between expression of major histocompatibility complex class I and that of antigen presenting machineries in carcinoma cell lines of the pancreas, biliary tract and colon.
Imanishi T; Kamigaki T; Nakamura T; Hayashi S; Yasuda T; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Kobe J Med Sci; 2006; 52(3-4):85-95. PubMed ID: 16855371
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Buck E; Eyzaguirre A; Haley JD; Gibson NW; Cagnoni P; Iwata KK
Mol Cancer Ther; 2006 Aug; 5(8):2051-9. PubMed ID: 16928826
[TBL] [Abstract][Full Text] [Related]
11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
12. The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules.
Belicha-Villanueva A; Riddell J; Bangia N; Gollnick SO
Lasers Surg Med; 2012 Jan; 44(1):60-8. PubMed ID: 22246985
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway.
Velásquez LN; Milillo MA; Delpino MV; Trotta A; Mercogliano MF; Pozner RG; Schillaci R; Elizalde PV; Giambartolomei GH; Barrionuevo P
Immunol Cell Biol; 2017 Apr; 95(4):388-398. PubMed ID: 27811842
[TBL] [Abstract][Full Text] [Related]
14. Selective autophagy of MHC-I promotes immune evasion of pancreatic cancer.
Yamamoto K; Venida A; Perera RM; Kimmelman AC
Autophagy; 2020 Aug; 16(8):1524-1525. PubMed ID: 32459143
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells.
Liang YH; Chen KH; Tsai JH; Cheng YM; Lee CC; Kao CH; Chan KY; Chen YT; Hsu WL; Yeh KH
J Biomed Sci; 2021 Nov; 28(1):75. PubMed ID: 34758826
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
Walters DM; Lindberg JM; Adair SJ; Newhook TE; Cowan CR; Stokes JB; Borgman CA; Stelow EB; Lowrey BT; Chopivsky ME; Gilmer TM; Parsons JT; Bauer TW
Neoplasia; 2013 Feb; 15(2):143-55. PubMed ID: 23441129
[TBL] [Abstract][Full Text] [Related]
17. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.
Keating S; Prince S; Jones M; Rowe M
J Virol; 2002 Aug; 76(16):8179-88. PubMed ID: 12134023
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor-induced protection of tumour cell susceptibility to cytolysis.
Nouri AM; Hussain RF; Oliver RT
Eur J Cancer; 1995 Jun; 31A(6):963-9. PubMed ID: 7544146
[TBL] [Abstract][Full Text] [Related]
19. Clustering of Major Histocompatibility Complex-Class I Molecules in Healthy and Cancer Colon Cells Revealed from Their Nanomechanical Properties.
Moretti M; La Rocca R; Perrone Donnorso M; Torre B; Canale C; Malerba M; Das G; Sottile R; Garofalo C; Achour A; Kärre K; Carbone E; Di Fabrizio E
ACS Nano; 2021 Apr; 15(4):7500-7512. PubMed ID: 33749234
[TBL] [Abstract][Full Text] [Related]
20. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Miyashita T; Miki K; Kamigaki T; Makino I; Nakagawara H; Tajima H; Takamura H; Kitagawa H; Fushida S; Ahmed AK; Duncan MD; Harmon JW; Ohta T
Clin Exp Med; 2017 Feb; 17(1):19-31. PubMed ID: 26449615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
